Cargando…
Role of EGF inhibitors in the treatment of recurrent or metastatic squamous cell head and neck cancer
Squamous cell cancer of the head and neck (SCCHN) is a major contributor to morbidity and mortality worldwide. In recent years, inhibition of the epidermal growth factor receptor has become an established treatment strategy in SCCHN both in the up-front treatment and in the recurrent and metastatic...
Autor principal: | Lorch, Jochen H |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004660/ https://www.ncbi.nlm.nih.gov/pubmed/21188133 |
Ejemplares similares
-
Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck
por: Reuter, C W M, et al.
Publicado: (2007) -
Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Hsieh, Ronan W., et al.
Publicado: (2021) -
Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands
por: van der Linden, Naomi, et al.
Publicado: (2015) -
Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Borel, Christian, et al.
Publicado: (2020) -
Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck.
por: Ishitoya, J., et al.
Publicado: (1989)